Clarinex extension
This article was originally published in The Tan Sheet
Executive Summary
FDA has approved Clarinex-D 12-Hour extended release tablets, Schering announces Feb. 1. The new formulation (desloratadine 2.5 mg/pseudoephedrine sulfate 120 mg) features a bi-layer tablet delivery system to control the release of the pseudoephedrine. The drug will be available in March, in time for allergy season, Schering notes. Separately, Claritin sales decreased 29% to $54 mil. during the fourth quarter of 2005, the company reports in an earnings call Jan. 30. Decreased Claritin-D (loratadine/pseudoephedrine) sales were attributed to PSE retail restrictions. Lower Claritin revenues, as well as a dip in sales of other pseudoephedrine-containing products contributed to a 9% decline in Consumer Health Care sales from the prior-year period to $198 mil. for the quarter. Adjusted net sales for the firm overall increased 13% to $2.7 bil. in the quarter, signaling the firm's move "from survive mode into thrive mode," CEO Fred Hassan states...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.